Thompson Street Capital Partners' portfolio company Tropichem Research Labs, LLC acquires TetraGenx

Date Closed

March 21, 2018

Lead Office


On March 21, 2018, Tropichem Research Labs, LLC acquired TetraGenx.

Tropichem is a portfolio company of St. Louis-based private equity firm Thompson Street Capital Partners. Tropichem develops, manufactures and packages animal care, personal care and household and industrial products out of its facility in Florida.

Montreal-based TetraGenx is a leading independent animal health contract development and manufacturing organization. TetraGenx specializes in complex drug product formulation development to create innovative pharmaceutical, over-the-counter and nutraceutical veterinary pharma products. Its services encompass four main categories, including product development (pre-formulation, formulation and analytical development), analytical testing, manufacturing and ancillary support services.

McCarthy Tétrault LLP advised Tropichem and Thompson Street Capital Partners with a team led by Patrick M. Shea and that included Cristel Chabot-Lapointe, Sarah Cote-Hamel, Thomas Etienne, Sven Milelli, Maureen Gillis, Suzanne Elie and Donna LeClair (Corporate and M&A); Marie-France Gagnon and Eve Tessier (Debt Financing); Véronique Wattiez Larose, Lisa Melanson, Vincent Yip, Benjamin Lai and Marissa Caldwell (Intellectual Property and Regulatory); Christian Meighen, Nicolas Désy, Angelo Discepola, Andrew Haikal and Alexandra Carbone (Tax); Diana Theophilopoulos (Labour and Employment); Madeleine Renaud (Competition and Foreign Investment Review); Dominique Amyot-Bilodeau (Environmental); Randy Bauslaugh and Kelleher Lynch (Employee Benefits); and Mary Pagonis and Mahsa Khoshbin (Real Estate).